Inovio Pharmaceuticals (NASDAQ: INO)has seen more downs than ups over the last three years. While the biotech stock is up a little so far in 2018, Inovio's share price has fallen more than 30% over the last 12 months and 56% over the last three years.
Is Inovio Pharmaceuticals, Inc. (INO) a Buy?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться